PMID- 34610580
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20220328
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 13
IP  - 19
DP  - 2021 Oct 5
TI  - Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes 
      mellitus patients than paroxetine/fluoxetine.
PG  - 22934-22946
LID - 10.18632/aging.203586 [doi]
AB  - Agomelatine was a novel and melatonergic antidepressant. The present study was 
      conducted to find out whether age was an important factor for agomelatine in 
      treating depressed type 2 diabetes mellitus (T2DM) patients. In total, 193 
      depressed T2DM patients were included. There were 84 patients ranged from 27 
      years old to 49 years old (age phase I) (n = 44 receiving agomelatine, n = 40 
      receiving paroxetine or fluoxetine), and 109 patients ranged from 50 years old to 
      70 years old (age phase II) (n = 56 receiving agomelatine, n = 53 receiving 
      paroxetine or fluoxetine). The Hamilton Depression Rating Scale (HDRS) score, 
      Hamilton Anxiety Rating Scale (HARS) score, fasting plasma glucose (FPG), 
      hemoglobin A1c (HbA1c) level and body mass index (BMI) were assessed after 12 
      weeks treatment. After treatment, we found that among patients in age phase I, 
      there were no significant differences in final average HDRS score, HARS score, 
      FPG, HbA1c level, BMI, response rate and remission rate between the two groups. 
      However, among patients in age phase II, compared to patients receiving 
      paroxetine or fluoxetine, patients receiving agomelatine had the significantly 
      lower average HDRS score, HARS score, HbA1c level and BMI, and significantly 
      higher response rate and remission rate. The incidence of treatment-related 
      adverse events was similar between the two groups in both age phases. These 
      results suggested that age was an important factor for agomelatine in treating 
      depressed T2DM patients. Compared to paroxetine/fluoxetine, agomelatine might be 
      more appropriate for elderly depressed T2DM patients.
FAU - Liang, Zihong
AU  - Liang Z
AD  - Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia 010017, People's Republic of China.
FAU - Jia, Yanbo
AU  - Jia Y
AD  - Department of Orthopaedics, The Second Affiliated Hospital of Inner Mongolia 
      Medical University, Huhhot, Inner Mongolia 010030, People's Republic of China.
FAU - Zhao, Lizhen
AU  - Zhao L
AD  - Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia 010017, People's Republic of China.
FAU - Zhu, Runxiu
AU  - Zhu R
AD  - Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia 010017, People's Republic of China.
FAU - He, Xuemei
AU  - He X
AD  - Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia 010017, People's Republic of China.
FAU - Tong, Bagen
AU  - Tong B
AD  - Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia 010017, People's Republic of China.
FAU - Yang, Fan
AU  - Yang F
AD  - Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia 010017, People's Republic of China.
FAU - Hao, Lixia
AU  - Hao L
AD  - Department of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia 010017, People's Republic of China.
FAU - Cui, Pengfei
AU  - Cui P
AD  - Department of Psychiatry, Inner Mongolia Autonomous Region Third Hospital, 
      Huhhot, Inner Mongolia 010050, People's Republic of China.
FAU - Yuan, Jun
AU  - Yuan J
AD  - Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia 010017, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20211005
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (Acetamides)
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Hypnotics and Sedatives)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 137R1N49AD (agomelatine)
RN  - 41VRH5220H (Paroxetine)
SB  - IM
MH  - Acetamides/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Aging
MH  - Antidepressive Agents, Second-Generation/therapeutic use
MH  - Depression/*drug therapy
MH  - *Diabetes Mellitus, Type 2
MH  - Female
MH  - Fluoxetine/*therapeutic use
MH  - Humans
MH  - Hypnotics and Sedatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Paroxetine/*therapeutic use
PMC - PMC8544326
OTO - NOTNLM
OT  - agomelatine
OT  - depression
OT  - fluoxetine
OT  - paroxetine
OT  - type 2 diabetes mellitus
COIS- CONFLICTS OF INTEREST: The authors declare no conflicts of interest related to 
      this study.
EDAT- 2021/10/06 06:00
MHDA- 2022/01/28 06:00
PMCR- 2021/10/15
CRDT- 2021/10/05 20:19
PHST- 2021/08/06 00:00 [received]
PHST- 2021/09/20 00:00 [accepted]
PHST- 2021/10/06 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
PHST- 2021/10/05 20:19 [entrez]
PHST- 2021/10/15 00:00 [pmc-release]
AID - 203586 [pii]
AID - 10.18632/aging.203586 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2021 Oct 5;13(19):22934-22946. doi: 10.18632/aging.203586. 
      Epub 2021 Oct 5.